In a large-scale clinical trial, the progression-free survival (PFS) of HER2+ advanced breast cancer patients treated with T-DM1 alone or in combination with chemotherapy is significantly longer than that of traditional treatment methods (75–77). The gene discussed is ERBB2; the disease is breast carcinoma.